Loading organizations...
Vida Ventures is a specialized life sciences investment firm that partners with companies to transform biomedical innovations into therapeutic solutions. The firm focuses on early-stage opportunities, applying a rigorous, science-led diligence process to identify and cultivate technologies addressing significant unmet medical needs, bridging discovery and patient benefit.
The firm was founded in 2017 by a distinguished collective of scientists, physicians, entrepreneurs, and investors: Arie Belldegrun, Arjun Goyal, Fred Cohen, Leonard A. Potter, and Stefan Vitorovic. Their foundational insight was the critical need for specialized capital and expertise to propel scientific breakthroughs into clinical development. Belldegrun, known for his leadership in successful biopharmaceutical ventures, exemplifies the deep industry experience guiding their strategy.
Vida Ventures supports entrepreneurial teams developing novel medicines to improve patient outcomes. Their long-term vision is to foster an environment where scientific advancements are nurtured and rapidly translated into accessible treatments. By advancing transformative biomedical innovations, the firm seeks to make a meaningful, lasting difference in patients’ lives globally.
Key people at Vida Ventures.
Vida Ventures was founded in 2017 by Fred Cohen (Co-Founder & Sr. Managing Director) and Leonard A. Potter (Co-Founder).
Vida Ventures was founded in 2017 by Fred Cohen (Co-Founder & Sr. Managing Director) and Leonard A. Potter (Co-Founder).
Vida Ventures is a next-generation life sciences investment firm focused on advancing transformative biomedical innovations that can significantly improve patient outcomes. Founded in 2017, the firm combines scientific expertise and entrepreneurial rigor to build and fund breakthrough companies in biomedicine. With approximately $1.8 billion under management and offices across Boston, Los Angeles, New York, and Fort Worth, Vida targets early-stage to growth investments in biomedical companies, emphasizing science-led, patient-centric innovation. Their portfolio spans cutting-edge areas such as genetic medicines, cell engineering, and novel drug discovery platforms, reflecting a disciplined approach to identifying and scaling high-impact science[1][2][3].
Vida Ventures was founded in 2017 by a coalition of scientists, physicians, entrepreneurs, and investors, including prominent life sciences leader Dr. Arie Belldegrun. The founding team’s deep scientific and clinical backgrounds shaped the firm’s mission to "bring science to life" by funding biomedical breakthroughs with real patient impact. Initially backed by a network of ultra-high-net-worth individuals, the firm has evolved to manage large institutional capital from endowments, foundations, sovereign wealth funds, and other sophisticated investors. Over time, Vida has expanded its geographic footprint and broadened its investment focus to encompass a multi-pillar strategy that supports companies from early platform creation through later-stage clinical and strategic milestones[1][2][4][5].
Vida Ventures operates at the intersection of several powerful trends in biotechnology and life sciences, including the rise of genetic medicines, cell and gene therapy, and platform-based drug discovery. The timing is critical as advances in molecular biology, computational biology, and translational medicine create unprecedented opportunities to develop novel therapies for unmet medical needs. Vida’s approach aligns with market forces favoring precision medicine and personalized therapies, positioning it as a key enabler in the ecosystem by bridging scientific innovation and commercial development. Its influence extends beyond capital provision to shaping the future of medicine through strategic partnerships and fostering a collaborative innovation environment[1][2][3].
Looking ahead, Vida Ventures is poised to continue expanding its portfolio with a focus on pioneering biomedical platforms and therapies that address complex diseases. Trends such as AI-driven drug discovery, advanced cell engineering, and next-generation genetic medicines will likely shape its investment strategy. As the firm deepens its scientific rigor and operational capabilities, its influence in accelerating the translation of breakthrough science into patient-impacting therapies is expected to grow. Vida’s commitment to bold, patient-first innovation suggests it will remain a leading force in life sciences venture capital, driving both scientific and commercial success in the evolving biotech landscape[2][3][5].
Key people at Vida Ventures.
Vida Ventures has more than 26 tracked investments across 21 companies. The latest tracked deal is $45.0M Series A Extension in Poplar Therapeutics in March 2026.
